Clinical Trial Update: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension [Phase 3]

View source ↗

Summary

The update covers completion of the Phase 3 DORADO-AC trial evaluating optimized doses of darusentan versus an active control in resistant hypertension. The sni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Darusentan (darusentan)

Snippet

Sponsor: Gilead Sciences | Conditions: Hypertension | Phase 3 | Status: COMPLETED